Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inventiva S.A.
An adverse reaction in lanafibranor’s Phase III trial leaves the company even more reliant on the upcoming LEGEND readout.
Crunch time is coming for a handful of companies expecting hugely consequential clinical readouts by the end of Q1 2024.
Inventiva’s pan-PPAR agonist and Terns’ combination strategy are targeting the NASH treatment paradigm after expected approval of Madrigal’s resmetirom. Viking is hoping to prove a better THRβ drug profile than Madrigal.
With its GLP-1 analog already a stalwart in type 2 diabetes and weight loss, Novo Nordisk is investigating semaglutide as monotherapy and in combination regimens to treat non-alcoholic steatohepatitis.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Inventiva Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.